<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02470507</url>
  </required_header>
  <id_info>
    <org_study_id>CSP88220</org_study_id>
    <nct_id>NCT02470507</nct_id>
  </id_info>
  <brief_title>Immune Function in Acute Kidney Injury</brief_title>
  <official_title>Evaluation of Immune Function in Patients With Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The immune response to kidney damage during acute kidney injury (AKI) is an important&#xD;
      contributor to the prolonged lack of renal function and progression of kidney injury. Most&#xD;
      data related to intrarenal and interorgan pathways in AKI stem from animal research with&#xD;
      sometimes conflicting results. Accurate evaluation of these processes in humans and&#xD;
      identification of early diagnostic tools are critical for the development of strategies to&#xD;
      prevent and attenuate AKI-related morbidity and mortality in patients.&#xD;
&#xD;
      The aim of this study is to evaluate immune function and miRNA expression in hospitalised&#xD;
      patients with and without AKI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis:&#xD;
&#xD;
      An overriding pro-inflammatory immune response underlies AKI in humans which contributes to&#xD;
      dysfunction of non-renal organs&#xD;
&#xD;
      Principal research question:&#xD;
&#xD;
      Is AKI in humans associated with a predominantly pro-inflammatory immune response?&#xD;
&#xD;
      Secondary research questions:&#xD;
&#xD;
        1. Does AKI affect the phenotypic characterisation and function of neutrophils?&#xD;
&#xD;
        2. Does severity of AKI lead to differences in phenotypic characterisation and function of&#xD;
           neutrophils?&#xD;
&#xD;
        3. What are the differences in cytokine profiles between AKI patients with and without&#xD;
           systemic inflammation?&#xD;
&#xD;
        4. What are the differences in cytokine profiles between AKI patients with systemic&#xD;
           inflammation and patients with systemic inflammation without AKI?&#xD;
&#xD;
        5. Is there a correlation between microRNA levels in patients with AKI and degree of AKI,&#xD;
           renal recovery and patient outcome?&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Observational non-interventional study&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      30 patients with AKI stage II or III * and systemic inflammation without sepsis 30 patients&#xD;
      with AKI stage II or III * and no systemic inflammation 30 patients with systemic&#xD;
      inflammation and normal renal function 30 patients after major surgery who do not have an&#xD;
      infection, SIRS or AKI&#xD;
&#xD;
      * AKI will be defined by the KDIGO criteria&#xD;
&#xD;
      Primary outcome Detection of measurable phenotypic characteristics and function of leukocytes&#xD;
      that are specific of patients with AKI.&#xD;
&#xD;
      Secondary outcomes:&#xD;
&#xD;
        1. Differences in phenotypic characterisation and function of neutrophils between patients&#xD;
           with AKI stage II and III.&#xD;
&#xD;
        2. Differences in phenotypic characterisation and function of neutrophils between patients&#xD;
           with and without AKI.&#xD;
&#xD;
        3. Differences in cytokine profiles between patients with AKI and systemic inflammation and&#xD;
           patients with AKI without systemic inflammation&#xD;
&#xD;
        4. Differences in cytokine profiles between AKI patients with systemic inflammation and&#xD;
           patients with systemic inflammation without AKI&#xD;
&#xD;
        5. Correlation between microRNA levels in patients with AKI and renal recovery&#xD;
&#xD;
        6. Correlation between microRNA levels in patients with AKI and patient outcome&#xD;
&#xD;
        7. Differences in cytokine profiles between AKI patients without systemic inflammation and&#xD;
           patients without AKI and without systemic inflammation / infection.&#xD;
&#xD;
      Statistical analysis:&#xD;
&#xD;
      For the analysis of laboratory variables that describe the immunological phenotype, standard&#xD;
      statistical methods will be applied. 1) When the normal distribution assumption is met,&#xD;
      groups will be compared using ANOVA and the corresponding contrasts for group by group&#xD;
      comparisons; 2) In the absence of normality or for ordinal variables, Kruskal Wallis will be&#xD;
      applied for multi-group comparisons, and Wilcoxon for two-groups analysis. We will apply&#xD;
      multiple testing correction via Benjamini-Hochberg FDR control.&#xD;
&#xD;
      For the analysis of miRNA array data, we will first follow the protocol quality control&#xD;
      measures appropriate for the platform of choice, and subsequently will carry out statistical&#xD;
      analysis using the SAMr and LIMMA packages from Bioconductor, via the R software. Similarly,&#xD;
      for the analysis of PCR data, the package HTqPCR from bioconductor will be used for quality&#xD;
      control. Depending on the distribution of the final data, either non-parametric statistics,&#xD;
      or a moderated t-test will be applied for statistical comparisons, with the corresponding&#xD;
      multiple testing corrections as above.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Phenotypic characteristics and function of leukocytes</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in phenotypic characterisation and function of neutrophils between AKI stage II and III.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in phenotypic characterisation and function of neutrophils between AKI and no AKI</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in cytokine profiles between AKI + SIRS and AKI without SIRS</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in cytokine profiles between SIRS + AKI and SIRS without AKI</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between microRNA levels in patients with AKI and renal recovery</measure>
    <time_frame>7 days</time_frame>
    <description>Correlation between microRNA levels in patients with AKI and patient outcome Differences in cytokine profiles between AKI patients without systemic inflammation and patients without AKI and without systemic inflammation / infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between microRNA levels in patients with AKI and patient outcome</measure>
    <time_frame>7 days</time_frame>
    <description>Differences in cytokine profiles between AKI patients without systemic inflammation and patients without AKI and without systemic inflammation / infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in cytokine profiles between AKI patients without SIRS and patients without AKI and without SIRS</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Kidney Failure</condition>
  <arm_group>
    <arm_group_label>AKI with SIRS</arm_group_label>
    <description>Patients with AKI stage II or III and systemic inflammation without sepsis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AKI without SIRS</arm_group_label>
    <description>Patients with AKI stage II or III and no systemic inflammation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SIRS without AKI</arm_group_label>
    <description>Patients with systemic inflammation and normal renal function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No SIRS and no AKI</arm_group_label>
    <description>Patients after major surgery who do not have an infection, SIRS or AKI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AKI</intervention_name>
    <description>development of immune dysregulation and rise in inflammatory markers and activation of immune cells</description>
    <arm_group_label>AKI with SIRS</arm_group_label>
    <arm_group_label>AKI without SIRS</arm_group_label>
    <arm_group_label>No SIRS and no AKI</arm_group_label>
    <arm_group_label>SIRS without AKI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalised patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (â‰¥ 18 years) admitted to the hospital (incl ICU) with one of the&#xD;
             following:&#xD;
&#xD;
               1. postoperative AKI II or III and systemic inflammation without sepsis&#xD;
&#xD;
               2. systemic inflammation and normal renal function&#xD;
&#xD;
               3. AKI II or III without systemic inflammation&#xD;
&#xD;
               4. post-surgery with normal renal function and without SIRS or an infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal transplant patients&#xD;
&#xD;
          -  Patients on immunosuppressive drugs (except steroids)&#xD;
&#xD;
          -  Patients with haematological malignancy&#xD;
&#xD;
          -  Jehovah's witness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlies Ostermann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's &amp; St Thomas NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guy's &amp; St Thomas Foundation Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

